CPI203

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CPI 203 (TEN 010, JQ-2, RG-6146) is a primary amide analog of (+)-JQ1and a BET bromodomain inhibitor that shows cytotoxicity against MCL cell lines with GI50 of 0.1-0.3 uM.

CPI 203 (TEN 010, JQ-2, RG-6146) is a primary amide analog of (+)-JQ1and a BET bromodomain inhibitor that shows cytotoxicity against MCL cell lines with GI50 of 0.1-0.3 uM; synergizes the antitumor activity of lenalidomide in bortezomib-resistant mantle cell lymphoma; also enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors, overcomes resistance to ABT-199 (Venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

TEN 010;JQ-2;RG-6146

Chromatin/Epigenetic

Bromodomain

BRD4

Cancer

——

1446144-04-2

399.90

C19H18ClN5OS

>98% (HPLC)

DMSO: 72 mg/mL (180 mM); Ethanol: 5 mg/mL (12.5 mM); Water: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(N)C[C@H]1C2=NN=C(C)N2C3=C(C(C)=C(C)S3)C(C4=CC=C(Cl)C=C4)=N1

(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide

(-20℃)

With Ice Pack

≥ 2 years